Sugi Predict

Sugi Predict / Compounds / SCHEMBL1763343

SCHEMBL1763343

SCHEMBL1763343

Fc1cnc(Cl)c2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.44
▸ TNF P01375 1/20 0.40
▸ RIPK1 Q13546 1/20 0.40
▸ AXL P30530 2/20 0.37
▸ PRKCI P41743 2/20 0.37
▸ NUDT1 P36639 1/20 0.37
▸ AHR P35869 1/20 0.34
▸ CCR8 P51685 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ TGFBR1 P36897 1/20 0.32
▸ GRM4 Q14833 1/20 0.32
▸ MKNK1 Q9BUB5 1/20 0.30
▸ MKNK2 Q9HBH9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30465845 0.85 DYRK1A (0.40) DYRK1ATNFRIPK1AXLPRKCI
SCHEMBL19792317 0.85 DYRK1A (0.40) DYRK1ATNFRIPK1AXLPRKCI
SCHEMBL12491412 0.80 DYRK1A (0.47) DYRK1ATNFRIPK1AXLPRKCI
SCHEMBL10069068 0.78 NUDT1 (0.38) DYRK1ATNFRIPK1AXLPRKCI
SCHEMBL31279052 0.77 DYRK1A (0.44) DYRK1AAXLPRKCIAHRCCR8
SCHEMBL31452765 0.77 DYRK1A (0.44) DYRK1AAXLPRKCIAHRCCR8
SCHEMBL9942629 0.77 DYRK1A (0.44) DYRK1AAXLPRKCIAHRCCR8
SCHEMBL1763170 0.77 NUDT1 (0.37) TNFRIPK1AXLPRKCINUDT1
SCHEMBL2633340 0.77 PIK3C3 (0.41) DYRK1ATNFRIPK1AXLPRKCI
SCHEMBL2628869 0.77 AXL (0.53) DYRK1AAXLPRKCIAHRCCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219460-B1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA INC (US) 2025-02-26 — — EP disclosed
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC., 2025-01-09 — — US disclosed
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2024-11-26 — — US disclosed
EP-4219460-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS Sitari Pharma, Inc. (US) 2023-08-02 — — EP disclosed
EP-4219460-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS Sitari Pharma, Inc. (US) 2023-08-02 — — EP disclosed
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2023-01-10 — — US disclosed
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2023-01-10 — — US disclosed
EP-3833348-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC (US) 2021-06-16 — — EP disclosed
US-20210163480-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC. 2021-06-03 — — US disclosed
US-20210163480-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC. 2021-06-03 — — US disclosed
US-6632819-B1 HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY 2003-10-14 — — US disclosed
US-20030181463-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-09-25 — — US disclosed
US-20030069266-A1 Aids therapy VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) 2003-04-10 — — US disclosed
CN-1404392-A Antiviral azaindole derivatives BRISTOL MYERS SQUIBB CO (US) 2003-03-19 — — CN disclosed
EP-1257276-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-11-20 — — EP disclosed
US-6476034-B2 AIDS THERAPY BRISTOL-MYERS SQUIBB COMPANY 2002-11-05 — — US disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 — — US disclosed
WO-2002062423-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 — — WO disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 — — US disclosed
WO-2001062255-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 DYRK1A 3956/4885TNF 3388/4885RIPK1 1033/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 DYRK1A 3956/4885TNF 3388/4885RIPK1 1033/4885
US-20210163480-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS TGM2, TGM3, TGM1 DYRK1A 2516/4885TNF 3640/4885RIPK1 2858/4885
US-11548892-B1 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 DYRK1A 2516/4885TNF 3640/4885RIPK1 2858/4885
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 DYRK1A 2516/4885TNF 3640/4885RIPK1 2858/4885
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS TGM2, TGM3, TGM1 DYRK1A 2516/4885TNF 3640/4885RIPK1 2858/4885
US-20030069266-A1 Aids therapy ENTPD5, CCR5, ITPA DYRK1A 4700/4885TNF 250/4885RIPK1 1561/4885
US-20030181463-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 DYRK1A 3956/4885TNF 3388/4885RIPK1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.